MARKETS
Earnings

Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate

Aug 11, 2026 · 07:33 AM ET· updated 2h ago

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the

Share
Why It Matters

Upstream Bio lost less money per share than expected, and made way more sales than people thought it would. When a company that's still losing money shows it's selling more stuff, that means its business is growing faster than investors guessed.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.